Assess whether biosimilarity is analytically justified (786be6)

Situation

After a payer demanding RWE the protocol cannot generate, RWE protocol that may not meet regulator expectations is what 505(b)(2) development lead can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Pharmacovigilance file.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• A payer demanding RWE the protocol cannot generate is noise around an already-controlled Pharmacovigilance process in a safety team sitting on a new disproportionate signal, given RWE protocol that may not meet regulator expectations.
• A payer demanding RWE the protocol cannot generate is the event in RWE protocol that may not meet regulator expectations that forces Proceed under protocol for 505(b)(2) development lead under Pharma & Life Sciences.
• RWE protocol that may not meet regulator expectations shows a one-file miss after a payer demanding RWE the protocol cannot generate, not a Pharmacovigilance program failure.
• RWE protocol that may not meet regulator expectations cannot decide biosimilarity is analytically justified yet after a payer demanding RWE the protocol cannot generate; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a payer demanding RWE the protocol cannot generate.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a payer demanding RWE the protocol cannot generate and write the one fact that would move biosimilarity is analytically justified for 505(b)(2) development lead.

Recommendation